-->

Tag: Locally Advanced Cancer

Home / Locally Advanced Cancer

Categories

Cosibelimab-ipdl is approved by the USFDA for metastatic or locally advanced cutaneous squamous cell carcinoma

 On December 13, 2024, the Food and Drug Administration sanctioned cosibelimab-ipdl (Unloxcyt, Checkpoint Therapeutics, Inc.), a programmed death ligand-1 (PD-L1) inhibiting antibody, for adults with...
locally-advanced-cancer

Osimertinib is approved by the USFDA for locally advanced, unresectable (stage III) non-small cell lung cancer following chemoradiation therapy

 On September 25, 2024, the Food and Drug Administration sanctioned osimertinib (Tagrisso, AstraZeneca Pharmaceuticals) for adult patients with locally advanced, unresectable (stage III) non-small ce...
locally-advanced-cancer

Scan the code